FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON

Their core work

IECSCYL is a health sciences research foundation based in Soria, Spain, specializing in hematological cancers and regenerative medicine for neurological conditions. They coordinate large-scale European data platforms for blood cancers — aggregating real-world patient data across leukemia, lymphoma, myeloma, and myelodysplastic syndromes to improve treatment outcomes. Beyond hematology, they contribute to research on brain repair therapies (stem cells for stroke, biohybrid systems for epilepsy) and early-stage Alzheimer's diagnostics using nanotechnology. Their work bridges clinical data science with translational medicine, turning big patient datasets into actionable treatment insights.

What they specialise in

How they've shifted over time

IECSCYL's early H2020 work (2015–2017) centered on regenerative medicine — stem cell therapies for stroke, tissue regeneration for graft-versus-host disease, and nanotechnology-based Alzheimer's diagnostics. From 2017 onward, the foundation pivoted decisively toward hematological oncology and clinical data science, coordinating the massive HARMONY consortium and its successor HARMONY PLUS, which aggregate real-world patient data across blood cancers. Their most recent projects (2020–2021) show a further expansion into precision oncology tools — NGS diagnostics, liquid biopsies, and cardio-oncology — suggesting they are embedding their hematology platform within a broader precision medicine ecosystem.

IECSCYL is moving from clinical research participation toward becoming a data-driven precision medicine hub for blood cancers, increasingly integrating genomics and real-world evidence platforms.

How they like to work

IECSCYL operates primarily as a consortium participant but has demonstrated strong leadership capacity — they coordinated the HARMONY alliance (EUR 7M, the largest hematology data initiative in Europe) and its follow-up HARMONY PLUS. With 144 unique partners across 17 countries, they have built an exceptionally wide network for a regional research foundation. This combination of broad network reach and proven coordination of large multi-stakeholder alliances makes them a reliable partner who can both lead and contribute.

With 144 unique consortium partners across 17 countries, IECSCYL has built a remarkably extensive European network — largely driven by the massive HARMONY alliance. Their reach spans well beyond Iberia into Northern and Central Europe, reflecting the pan-European scope of hematology research collaboration.

What sets them apart

IECSCYL's standout asset is their role as architect and coordinator of Europe's premier hematology big data platform (HARMONY), which aggregates real-world patient data across all major blood cancers. For a regional foundation based in Soria rather than Madrid or Barcelona, this is a remarkable position — they punch far above their geographic weight class. Any consortium needing access to large-scale hematology patient data, translational medicine expertise, or a proven coordinator for complex multi-country health data projects should consider them a top-tier partner.

Highlights from their portfolio

• HARMONY
  Largest project by far (EUR 7M), coordinated by IECSCYL — built Europe's biggest hematology big data platform across all major blood cancer types.
• HARMONY PLUS
  Follow-up coordination (EUR 1.6M) extending the HARMONY platform into translational medicine, digital health outcomes, and sustainable business models.
• HERMES
  Unusual cross-disciplinary project combining biohybrid systems, neuromorphic engineering, and AI for brain repair — signals emerging capabilities beyond traditional clinical research.